Microenvironmental Hypoxia regulates FLT3 expression and biology in AML

被引:14
|
作者
Sironi, Silvia [1 ]
Wagner, Michaela [1 ]
Kuett, Alexander [1 ]
Drolle, Heidrun [1 ]
Polzer, Harald [1 ,2 ,3 ,4 ]
Spiekermann, Karsten [1 ,2 ,3 ,4 ]
Rieger, Christina [1 ]
Fiegl, Michael [1 ]
机构
[1] Klinikum Univ Munchen, Dept Internal Med 3, Munich, Germany
[2] German Res Ctr Environm Hlth, Clin Cooperat Grp Leukemia, Helmholtz Zentrum Munchen, Munich, Germany
[3] German Canc Consortium DKTK, Heidelberg, Germany
[4] German Canc Res Ctr, Heidelberg, Germany
来源
SCIENTIFIC REPORTS | 2015年 / 5卷
关键词
ACUTE MYELOID-LEUKEMIA; BONE-MARROW; CONSTITUTIVE ACTIVATION; C-CBL; OXYGEN; PATHWAYS; KINASE; NICHE;
D O I
10.1038/srep17550
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Fms-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase constitutively expressed by acute myeloid leukaemia (AML) blasts. In addition, 25% of AML patients harbour a FLT3-ITD mutation, associated with inferior outcome due to increased relapse rate. Relapse might be propagated by interactions between AML blasts and the bone marrow microenvironment. Besides cellular elements of the microenvironment (e.g. mesenchymal stromal cells), bone marrow hypoxia has emerged as an additional crucial component. Hence, effects of hypoxia on FLT3 expression and biology could provide novel insight into AML biology. Here we show that 25% of AML patients down-regulate FLT3 expression on blasts in response to in vitro hypoxia (1% O-2), which was independent of its mutational state. While virtually no AML cell lines regulate FLT3 in response to hypoxia, the down-regulation could be observed in Ba/F3 cells stably transfected with different FLT3 mutants. Hypoxia-mediated down-regulation was specific for FLT3, reversible and proteasome-dependent; with FLT3 half-life being significantly shorter at hypoxia. Also, PI-3K inhibition could partially abrogate down-regulation of FLT3. Hypoxia-mediated down-regulation of FLT3 conferred resistance against cytarabine in vitro. In conclusion, FLT3 expression in AML is dependent on the oxygen partial pressure, but response to hypoxia differs.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] The growing landscape of FLT3 inhibition in AML
    Smith, Catherine C.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2019, : 539 - 547
  • [22] Inhibition of FLT3 in AML: a focus on sorafenib
    A Antar
    Z K Otrock
    J El-Cheikh
    M A Kharfan-Dabaja
    G Battipaglia
    R Mahfouz
    M Mohty
    A Bazarbachi
    Bone Marrow Transplantation, 2017, 52 : 344 - 351
  • [23] Targeted Therapy of FLT3 mutated AML
    Fiedler, W.
    Heuser, M.
    Kayser, S.
    Kebenko, M.
    Krauter, J.
    Salih, H. R.
    Goetze, K.
    Stamm, H.
    Latuske, E.
    Wellbrock, J.
    Doehner, K.
    Ganser, A.
    Doehner, H.
    Schlenk, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 21 - 21
  • [24] Which FLT3 Inhibitor for Treatment of AML?
    Senapati, Jayastu
    Kadia, Tapan Mahendra
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022, 23 (03) : 359 - 380
  • [25] Which FLT3 Inhibitor for Treatment of AML?
    Jayastu Senapati
    Tapan Mahendra Kadia
    Current Treatment Options in Oncology, 2022, 23 : 359 - 380
  • [26] The Future of Targeting FLT3 Activation in AML
    Leick, Mark B.
    Levis, Mark J.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2017, 12 (03) : 153 - 167
  • [27] FLT3 Inhibitors in AML: Are We There Yet?
    Sudhindra, Akshay
    Smith, Catherine Choy
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2014, 9 (02) : 174 - 185
  • [28] Prognostic relevance of FLT3 mutations in AML
    Blau, O.
    Berenstein, R.
    Sindarm, A.
    Baldus, C. D.
    Blau, I. W.
    ONKOLOGIE, 2011, 34 : 77 - 77
  • [29] The Future of Targeting FLT3 Activation in AML
    Mark B. Leick
    Mark J. Levis
    Current Hematologic Malignancy Reports, 2017, 12 : 153 - 167
  • [30] A Review of FLT3 Kinase Inhibitors in AML
    Negotei, Cristina
    Colita, Andrei
    Mitu, Iuliana
    Lupu, Anca Roxana
    Lapadat, Mihai-Emilian
    Popovici, Constanta Elena
    Crainicu, Madalina
    Stanca, Oana
    Berbec, Nicoleta Mariana
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (20)